- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05541341
급성 림프구성 백혈병 또는 미만성 거대 B세포 림프종을 앓고 있는 브라질 환자에서 Tisagenlecleucel의 효과 및 안전성 연구
급성 림프구성 백혈병 또는 미만성 거대 B세포 림프종을 앓고 있는 브라질 환자에서 Tisagenlecleucel 요법의 효과 및 안전성: 두 코호트에 대한 15년 전향적 레지스트리 연구
This will be a multicenter, national, non-interventional, prospective cohort study
연구 개요
상세 설명
Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications.
Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a "Pre-infusion" and a "Post infusion follow-up period" for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.
For the study, "pre-infusion" and "follow-up post infusion" phases are defined as:
- "Pre-infusion" will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel.
- "Follow-up Post infusion" information will comprise any information from the infusionof tisagenlecleucel onwards.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Novartis Pharmaceuticals
- 전화번호: +41613241111
- 이메일: novartis.email@novartis.com
연구 연락처 백업
- 이름: Novartis Pharmaceuticals
연구 장소
-
-
-
São Paulo, 브라질, 01509-010
- 모병
- Novartis Investigative Site
-
São Paulo, 브라질, 01409-902
- 모병
- Novartis Investigative Site
-
-
Belo Horizonte
-
Minas Gerais, Belo Horizonte, 브라질, 34006-059
- 모병
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 41253-190
- 모병
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, 브라질, 81520-060
- 모병
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo, São Paulo, 브라질, 01323-900
- 모병
- Novartis Investigative Site
-
São Paulo, São Paulo, 브라질, 04544-000
- 모병
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
The study population will include pediatric/ adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia aged 0-25 years and adult patients aged ≥ 18 years with relapsed/refractory Diffuse Large B-cell Lymphoma and relapsed/refractory follicular lymphoma, who received tisagenlecleucel infusion in the commercial setting or out-of-specification.
설명
Inclusion Criteria:
Patients eligible for inclusion in this study must meet the following criteria:
-
Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND
-
Signed informed consent must be obtained prior to participation in study, AND
For ALL participants:
-
Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR
-
Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR
For DBLCL and FL participants:
-
Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.
Exclusion Criteria:
- Patients who did not consent to data collection.
- Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: OTHER
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Acute Lymphoblastic Leukemia (ALL)
Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion |
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study |
|
Diffuse Large B-cell Lymphoma (DLBCL)
Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion |
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study |
|
Follicular Lymphoma (FL)
Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion. |
Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall response rate (ORR)
기간: Up to 15 years
|
The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI. For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003). For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016). |
Up to 15 years
|
|
MRD negative overall response rate
기간: Up to 15 years
|
The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI. |
Up to 15 years
|
|
Duration of overall response (DOR)
기간: Up to 15 years
|
Duration of overall response (DOR) applies only to patients whose best overall disease response was either:
DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease. In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event. |
Up to 15 years
|
|
Relapse-free survival (RFS)
기간: Up to 15 years
|
RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients. In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event. |
Up to 15 years
|
|
Event-free survival (EFS) for ALL patients
기간: Up to 15 years
|
EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients. |
Up to 15 years
|
|
Progression free survival (PFS) for DLBCL patients
기간: Up to 15 years
|
PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment. In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event. |
Up to 15 years
|
|
Overall survival (OS)
기간: Up to 15 years
|
Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact. |
Up to 15 years
|
|
Number of ALL patients with hematologic recovery
기간: Up to 15 years
|
Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected. ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR). The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR). |
Up to 15 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The type and frequency of SAEs and AE of special interest
기간: Up to 15 years
|
The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected |
Up to 15 years
|
|
Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients
기간: Up to 15 years
|
Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients. For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading. For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years |
Up to 15 years
|
|
Pregnancy rates
기간: Up to 15 years
|
Pregnancy rates will be collected |
Up to 15 years
|
|
Number of patients with confirmed secondary malignancies diagnosis
기간: Up to 15 years
|
Number of patients with confirmed secondary malignancies diagnosis will be collected |
Up to 15 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CCTL019BBR02
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .